View Document Preview and Link Open Document File Size: 3,69 MB Share Result on Facebook
City Efficacy / / Company FAB / The STAR / Clinical Program Novalar Pharmaceuticals Incorporated / Novalar Pharmaceuticals Inc. / / Country United States / / Event FDA Phase / / Facility Laboratory Findings / / IndustryTerm injection solution / drug product / vasoconstrictor-containing local anesthetic drug product / / MedicalCondition soft tissue injury / nerve injury / bradycardia and increased blood pressure / reduced injury / only nerve injury / erythema / dermal necrosis / lingual nerve injury / Pain / drooling / injury / pheochromocytoma / self-inflicted injury / self-inflicted soft tissue injury / such injury / injuries / / Organization NV NV-101 administration / Food and Drug Administration Center for Drug Evaluation / Research Division of Anesthesia / Analgesia and Rheumatology Products / American Academy of Pediatric Dentistry1 / / Person Review Arthur Simone / May / Arthur Simone / Parker Visual Analog / / Position EXECUTIVE / General / / Product Phentolamine Mesylate / Formulation Dosing Regimen Indication injection / epinephrine / lidocaine / NV-101 / / ProvinceOrState Maryland / / PublishedMedium the STAR / / Technology PHARMACOKINETICS / PHARMACODYNAMICS / / SocialTag 
Phentolamine Clinical Pediatric Review